CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)

卡罗莱纳州癌症纳米技术培训计划 (C-CNTP)

• 批准号: 10650745
• 负责人: ALEXANDER V KABANOV
• 金额: $ 38.86万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10650745
• 关键词: Malignant Neoplasms; Nanotechnology; Training Programs

This proposal seeks competing continuation of the NIH T32 Carolina Cancer Nanotechnology Training Program (C-CNTP). The program started in 2015 with the support of the NIH Ruth L. Kirschstein National Research Service Award. The goal of the program is to make a major contribution to the growth of the cancer nanotechnology workforce by providing training and research experience to a highly select cohort of postdoctoral fellows. During four years since its initiation the program has recruited 15 excellent fellows of whom 5 have completed training and moved into tenure track assistant professors, industry and FDA positions, 8 continue training with the NIH T32 support and 2 are in the final stages of training with other support sources in the labs of their mentors. We have assembled a team of 20 outstanding Program faculty from 11 departments and 3 schools at the University of North Carolina Chapel Hill with specific expertise in physical and material sciences, chemistry, pharmacoengineering, drug delivery, computational modeling as well as basic biomedical research and clinical science, all of whom have demonstrated strong interests, capabilities and collaborations at the interface between nanoscience and cancer. The objectives of the C-CNTP are to: 1) recruit an elite group of talented postdoctoral fellows from diverse backgrounds with PhD, MD or PharmD and provide them with outstanding postdoctoral experience including focused didactic training and co-mentored research experience with faculty mentors from complementary fields; 2) provide each trainee with intensive introductory training with online video library of recorded lectures followed by workshops and didactic courses to remediate differences in their backgrounds and to deepen the knowledge and understanding in the key areas of cancer nanotechnology; and 3) facilitate transition of trainees to independence by providing them with opportunities to a) conduct original cancer nanotechnology research projects; b) apply for the individual cancer nanotechnology Pilot Grants within C-CNTP, and c) acquire written and oral communications skills needed to publish manuscripts, report results, and write successful individual extramural support applications focused on problems of cancer nanotechnology. We are committed to developing a world-class postdoctoral training program that capitalizes on the existing strengths in cancer nanotechnology research, consolidates diverse research and education resources across several academic units, and becomes a significant contributor to addressing the Nation's research needs in cancer nanotechnology.

该提案寻求 NIH T32 卡罗莱纳州癌症纳米技术培训计划的竞争延续 （C-CNTP）。该项目于 2015 年启动，得到了 NIH Ruth L. Kirschstein 国家研究中心的支持 服务奖。该计划的目标是为癌症的生长做出重大贡献 纳米技术劳动力，为精选的博士后群体提供培训和研究经验 各位。项目启动四年来，已招募了15名优秀研究员，其中5名拥有 完成培训并进入终身教授助理教授、行业和 FDA 职位，8 继续 在 NIH T32 支持下进行培训，其中 2 人正处于实验室其他支持来源的培训的最后阶段 他们的导师。我们组建了一支由来自11个系和3个学院的20名优秀项目教师组成的团队。 北卡罗来纳大学教堂山分校的学校在物理和材料科学方面具有特定的专业知识， 化学、药物工程、药物输送、计算模型以及基础生物医学研究 和临床科学，他们都在该领域表现出了浓厚的兴趣、能力和合作 纳米科学与癌症之间的界面。 C-CNTP 的目标是： 1) 招募精英团队 来自不同背景的优秀博士后研究员，拥有博士学位、医学博士或药学博士学位，并为他们提供 出色的博士后经验，包括重点教学培训和共同指导的研究经验 来自互补领域的教师导师； 2）为每位学员提供强化的入门培训 录制讲座的在线视频库，随后举办研讨会和教学课程，以弥补不同方面的差异 他们的背景并加深对癌症纳米技术关键领域的知识和理解； 3) 通过为受训者提供以下机会来促进他们向独立过渡： 癌症纳米技术研究项目； b) 申请个人癌症纳米技术试点补助金 C-CNTP，以及 c) 获得发表手稿、报告结果、 并撰写成功的个人校外支持申请，重点关注癌症纳米技术问题。 我们致力于利用现有的资源开发世界一流的博士后培训计划 癌症纳米技术研究的优势，整合了不同领域的研究和教育资源 多个学术单位，并成为满足国家研究需求的重要贡献者 癌症纳米技术。

项目成果

Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic Agents.

肺腺癌原位同基因模型的制备以及化疗和免疫治疗剂聚（2-恶唑啉）制剂的抗肿瘤功效测试。

• DOI: 10.21769/bioprotoc.3953
• 发表时间: 2021
• 期刊: Bio-protocol
• 影响因子: 0.8
• 作者: Vinod,Natasha;Hwang,Duhyeong;Azam,SalmaH;VanSwearingen,AmandaED;Wayne,Elizabeth;Fussell,SloaneChristian;Sokolsky-Papkov,Marina;Pecot,ChadV;Kabanov,AlexanderV
• 通讯作者: Kabanov,AlexanderV

Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment.

• DOI: 10.3389/fphar.2018.00307
• 发表时间: 2018
• 期刊: Frontiers in pharmacology
• 影响因子: 5.6
• 作者: Harrison EB;Azam SH;Pecot CV
• 通讯作者: Pecot CV

Influenza Virus and SARS-CoV-2 Vaccines.

• DOI: 10.4049/jimmunol.2001287
• 发表时间: 2021-06-01
• 期刊: Journal of immunology (Baltimore, Md. : 1950)
• 作者: Sandor AM;Sturdivant MS;Ting JPY
• 通讯作者: Ting JPY

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.

纤维蛋白凝胶增强胶质母细胞瘤中嵌合抗原受体 T 细胞的抗肿瘤作用。

• DOI: 10.1126/sciadv.abg5841
• 发表时间: 2021-10-08
• 期刊: Science advances
• 影响因子: 13.6
• 作者: Ogunnaike EA;Valdivia A;Yazdimamaghani M;Leon E;Nandi S;Hudson H;Du H;Khagi S;Gu Z;Savoldo B;Ligler FS;Hingtgen S;Dotti G
• 通讯作者: Dotti G

A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.

• DOI: 10.1016/j.jconrel.2018.06.002
• 发表时间: 2018-08-28
• 期刊: Journal of controlled release : official journal of the Controlled Release Society
• 作者: McSweeney MD;Wessler T;Price LSL;Ciociola EC;Herity LB;Piscitelli JA;Zamboni WC;Forest MG;Cao Y;Lai SK
• 通讯作者: Lai SK